Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
SWOG Cancer Research Network
Checkpoint Therapeutics, Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Calithera Biosciences, Inc
Spectrum Pharmaceuticals, Inc
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
Endocyte
Stanford University
Boehringer Ingelheim
National Cancer Institute (NCI)